ticlopidine has been researched along with Substance Withdrawal Syndrome in 13 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
Substance Withdrawal Syndrome: Physiological and psychological symptoms associated with withdrawal from the use of a drug after prolonged administration or habituation. The concept includes withdrawal from smoking or drinking, as well as withdrawal from an administered drug.
| Excerpt | Relevance | Reference |
|---|---|---|
| "tirofiban may allow temporary withdrawal of oral clopidogrel without increasing the risk of bleeding." | 2.75 | Urgent surgery in patients with a recently implanted coronary drug-eluting stent: a phase II study of 'bridging' antiplatelet therapy with tirofiban during temporary withdrawal of clopidogrel. ( Barlocco, F; Caracciolo, M; D'Urbano, M; De Servi, S; Klugmann, S; Mariani, G; Nichelatti, M; Savonitto, S, 2010) |
| " However, recent studies indicate that even discontinuation of long-term use of clopidogrel may be associated with multiple adverse outcomes, that is, rebound phenomenon whose mechanism is not definitely clear." | 1.40 | Clopidogrel cessation triggers aspirin rebound in patients with coronary stent. ( Djukanovic, N; Njegomirovic, S; Obradovic, S; Ostojic, M; Protić, D; Todorovic, Z; Zamaklar-Trifunovic, D, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (69.23) | 29.6817 |
| 2010's | 4 (30.77) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Djukanovic, N | 2 |
| Todorovic, Z | 2 |
| Obradovic, S | 2 |
| Njegomirovic, S | 2 |
| Zamaklar-Trifunovic, D | 2 |
| Protić, D | 1 |
| Ostojic, M | 2 |
| Graw, J | 1 |
| Schwenk, W | 1 |
| Volk, T | 1 |
| Jähne, J | 2 |
| Schirren, J | 2 |
| Rottbauer, W | 1 |
| Katus, HA | 1 |
| Bölükbas, S | 1 |
| Martens, A | 1 |
| Haverich, A | 1 |
| Savonitto, S | 1 |
| D'Urbano, M | 1 |
| Caracciolo, M | 1 |
| Barlocco, F | 1 |
| Mariani, G | 1 |
| Nichelatti, M | 1 |
| Klugmann, S | 1 |
| De Servi, S | 1 |
| Milic, NM | 1 |
| Prostran, M | 1 |
| Avlonitis, VS | 1 |
| Planas, S | 1 |
| Hayes, AM | 1 |
| Parry, A | 1 |
| Di Micco, B | 1 |
| Di Micco, G | 1 |
| Niglio, A | 1 |
| Romano, M | 1 |
| Di Micco, P | 1 |
| Angiolillo, DJ | 1 |
| Fernandez-Ortiz, A | 1 |
| Bernardo, E | 1 |
| Ramírez, C | 1 |
| Sabaté, M | 1 |
| Jimenez-Quevedo, P | 1 |
| Hernández, R | 1 |
| Moreno, R | 1 |
| Escaned, J | 1 |
| Alfonso, F | 1 |
| Bañuelos, C | 1 |
| Costa, MA | 1 |
| Bass, TA | 1 |
| Macaya, C | 1 |
| Murat, O | 1 |
| Durand, E | 1 |
| Delépine, G | 1 |
| Nguyen, P | 1 |
| Malinovsky, JM | 1 |
| Timurkaynak, T | 1 |
| Goksen, I | 1 |
| Cengel, A | 1 |
| Dortlemez, O | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Management of Antiplatelet Regimen During Surgical Procedures (MARS Registry)[NCT03981835] | 1,492 participants (Anticipated) | Observational [Patient Registry] | 2019-08-01 | Recruiting | |||
| Long Term Safety Study in Patients Included in the CLARINET Study With Cyanotic Congenital Heart Disease Palliated With a Systemic-to-pulmonary Artery Shunt and for Whom the Shunt is Still in Place at One Year of Age[NCT00833703] | Phase 3 | 49 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
For all reported bleeding events, the type and the etiology of the bleeding event were collected. Participants who experienced bleeding events during the 'on-treatment period' were counted by bleeding type and etiology. (NCT00833703)
Timeframe: Up to a maximum of 6 months
| Intervention | participants (Number) | |
|---|---|---|
| Spontaneous | Puncture (vascular access site) | |
| Clopidogrel 0.2 mg/kg/Day | 1 | 1 |
| Placebo | 0 | 0 |
"All bleeding events experienced during the study period were collected as for any Adverse Event.~The 'on-treatment' period was defined as the period from inclusion in the extension study up to 28 days after treatment discontinuation, and participants who experienced bleeding events during that period were counted." (NCT00833703)
Timeframe: Up to a maximum of 6 months
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Any bleeding event | - Serious | - Serious with an outcome of death | - Leading to permanent treatment discontinuation | |
| Clopidogrel 0.2 mg/kg/Day | 2 | 0 | 0 | 0 |
| Placebo | 0 | 0 | 0 | 0 |
"Outcome events, shunt thrombosis requiring intervention or death, experienced during the study period were recorded.~Participants were counted excluding the events that occured after the participant's protocol study end (occurrence of shunt thrombosis, next surgical procedure for correction of the congenital heart disease, death, or 18 months of age, whichever came first)." (NCT00833703)
Timeframe: Up to a maximum of 6 months
| Intervention | participants (Number) | |
|---|---|---|
| shunt thrombosis requiring intervention | death | |
| Clopidogrel 0.2 mg/kg/Day | 0 | 0 |
| Placebo | 0 | 1 |
1 review available for ticlopidine and Substance Withdrawal Syndrome
| Article | Year |
|---|---|
[Drug-eluting stents: implications for modern coronary revascularization].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Bias; Clopidogrel; Comorbidity; Coronary Artery Bypass; Cor | 2009 |
1 trial available for ticlopidine and Substance Withdrawal Syndrome
| Article | Year |
|---|---|
Urgent surgery in patients with a recently implanted coronary drug-eluting stent: a phase II study of 'bridging' antiplatelet therapy with tirofiban during temporary withdrawal of clopidogrel.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Blood Loss, Surgical; Clopidogrel; C | 2010 |
11 other studies available for ticlopidine and Substance Withdrawal Syndrome
| Article | Year |
|---|---|
Clopidogrel cessation triggers aspirin rebound in patients with coronary stent.
Topics: Aspirin; Clopidogrel; Drug Interactions; Female; Humans; Male; Middle Aged; Percutaneous Coronary In | 2014 |
[Perioperative discontinuation of antiplatelet therapy of patients with coronary stents. Reevaluating the risks].
Topics: Algorithms; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Restenosis; Decision Tree | 2009 |
[Introduction to the topic: drug eluting stents. An underestimated problem in surgery].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Restenosis; Drug-Eluting Stents; Hemo | 2009 |
[Patients with coronary artery stents: when and how should operations be carried out?].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Cooperative Behavior; Coronary Restenosis; Dru | 2009 |
[Drug-eluting stents: implications for surgery patients].
Topics: Algorithms; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Cooperative Behavior; Coronary Res | 2009 |
Abrupt cessation of one-year clopidogrel treatment is not associated with thrombotic events.
Topics: Aged; Clopidogrel; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Substance Wit | 2011 |
Occlusion of modified Blalock-Taussig shunt after clopidogrel cessation.
Topics: Anticoagulants; Aspirin; Blalock-Taussig Procedure; Clopidogrel; Fatal Outcome; Graft Occlusion, Vas | 2012 |
Proximal deep venous thrombosis occurring after sudden clopidogrel suspension.
Topics: Aged; Atrial Fibrillation; Clopidogrel; Humans; Male; Platelet Aggregation Inhibitors; Prognosis; Su | 2004 |
Clopidogrel withdrawal is associated with proinflammatory and prothrombotic effects in patients with diabetes and coronary artery disease.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Diabetes Complications; Diabetes Mellitus; Fema | 2006 |
[Spinal cord ischaemia and preoperative clopidogrel withdrawal in an arteriosclerotic patient].
Topics: Arteriosclerosis; Clopidogrel; Female; Humans; Middle Aged; Platelet Aggregation Inhibitors; Spinal | 2008 |
Adjunctive therapies in the cath lab. Subacute stent thrombosis developing twelve days after discontinuation of ticlopidine treatment.
Topics: Acute Disease; Aged; Coronary Thrombosis; Female; Humans; Platelet Aggregation Inhibitors; Stents; S | 2001 |